Skip to content
Cipla logo

Cipla

CIPLA NSE
₹1,402.00 +5.10 (+0.37%)
P/E
33.59
View as Markdown
MCP
Close 4 Nov 2026 ₹1,402.00 −99.50 −6.63% 1Y
Start ₹1,501.50

Key Fundamentals

LargecapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
15.50%
Debt to Equity
0.02
EPS (TTM)
₹41.74
Book Value
₹438.13
Market Cap
—
P/E (TTM)
33.59
P/B
3.20
ROE
11.60%
Dividend Yield
0.93%
EBITDA
₹6,765 Cr
52W High
₹1,539.70
52W Low
₹1,165.70
Day Range
₹1,386.00 – ₹1,402.00
Volume
13,22,399

Peer Comparison

Healthcare › Pharmaceuticals

Cipla peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla (this company)
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Median 7 companies₹1,773.4038.81₹1,25,446 Cr4.770.58%16.50%17.80%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

50 Average

Data confidence 100/100

Category scores

Quality
41
Weak
Returns, margins, earnings quality 22% weight
Valuation
71
Strong
Cheap vs sector & own history 24% weight
Growth
8
Poor
Sales & profit trajectory 9% weight
Financial Health
79
Strong
Solvency, leverage, coverage 9% weight
Momentum
21
Poor
Trend strength, vol-adjusted 12% weight
Ownership
51
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 25.7%

Weaknesses

2
  • The company has delivered a poor sales growth of 8.01% over past five years.
  • Promoter holding has decreased over last 3 years: -4.26%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish4312
OscillatorsBearish432
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
64.95
Neutral
MACD (12,26,9)
7.33
Bullish
SMA (50)
1,368.33
Bullish
SMA (200)
1,363.47
Bullish

As of

Analyst Rating

Based on 35 analysts
BUY63%

22 of 35 analysts rate Buy, 12 Hold, 1 Sell.

As of

BUY
22
63%
HOLD
12
34%
SELL
1
3%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+7.40%
5Y+8.01%
3Y+7.37%
1Y+2.23%
TTM+1.84%

Net profit

Net profit growth by window
10Y+10.82%
5Y+10.08%
3Y+10.88%
1Y−26.70%
TTM−37.69%

Operating cash flow

Operating cash flow growth by window
10Y+8.51%
5Y+0.97%
3Y+6.76%
1Y−21.28%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+2.91 pp
5Y−1.30 pp
3Y−1.20 pp
1Y−4.98 pp
TTM−7.16 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹14,394 Cr
Mar 2018₹15,156 Cr
Mar 2019₹16,362 Cr
Mar 2020₹17,132 Cr
Mar 2021₹19,160 Cr
Mar 2022₹21,763 Cr
Mar 2023₹22,753 Cr
Mar 2024₹25,774 Cr
Mar 2025₹27,548 Cr
Mar 2026₹28,163 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹1,035 Cr
Mar 2018₹1,417 Cr
Mar 2019₹1,492 Cr
Mar 2020₹1,500 Cr
Mar 2021₹2,389 Cr
Mar 2022₹2,547 Cr
Mar 2023₹2,833 Cr
Mar 2024₹4,154 Cr
Mar 2025₹5,269 Cr
Mar 2026₹3,862 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹1,594 Cr +6.0% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 30 Oct 2026
AI opinion · based on fundamentals
Risk medium

Cipla Ltd trades at ₹1,378.9 as of 2026-10-30 with a market cap of ₹1,10,539 crore and a P/E of 33.04x. The company is virtually debt-free with a debt-to-equity ratio of 0.02, but TTM profit growth has turned sharply negative at -34% and sales growth has slowed to 2% TTM, presenting a mixed picture of balance sheet strength against near-term earnings deterioration.

Bull Case 7
  • Near-zero leverage with a debt-to-equity ratio of just 0.02, providing significant financial flexibility and resilience against interest rate cycles.
  • Consistent long-term profitability with 10-year compounded profit growth of 11% and 5-year compounded profit growth of 10%, reflecting durable earnings power.
  • Healthy return ratios with 3-year average ROE of 15% and 5-year average ROE of 14%, indicating efficient capital allocation over extended periods.
  • Sustained dividend payout ratio of 25.7%, translating to a current dividend yield of 0.96%, offering income alongside capital appreciation potential.
  • ROCE of 14.88% as of 2026-10-30 suggests the business generates reasonable returns on total capital employed despite the recent earnings dip.
  • Stock is trading 10.5% below its 52-week high of ₹1,539.7, which may reflect some of the near-term headwinds already being priced in.
  • 10-year compounded sales growth of 7% demonstrates the company has been able to grow its topline steadily across multiple market cycles.
Bear Case 8
  • TTM profit has declined sharply at -34%, a significant reversal from the longer-term 10-year CAGR of 11%, signalling potential margin pressure or one-off impacts.
  • TTM sales growth has decelerated to just 2%, well below the 5-year compounded sales growth rate of 8%, indicating a meaningful revenue slowdown.
  • P/E of 33.04x appears elevated relative to the TTM earnings contraction of -34%, suggesting the stock may not yet fully reflect deteriorating fundamentals.
  • Promoter holding has declined by 4.26% over the last three years, which can signal reduced insider confidence or stake dilution.
  • Five-year compounded sales growth of only 8.01% is modest for a healthcare company trading at a P/E above 33x.
  • Last year ROE dropped to 12% from the 3-year average of 15%, indicating a declining trend in shareholder return efficiency.
  • 1-year stock CAGR of -16% reflects significant underperformance, and the 3-year stock CAGR of just 4% suggests prolonged muted returns for investors.
  • Price-to-book ratio of 3.15x paired with a declining ROE of 11.21% as of 2026-10-30 implies the premium over book value may be harder to justify if returns continue to compress.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Recent newsflow for Cipla is limited and largely procedural. The appointment of a seasoned operations leader as Global CTO signals continued focus on manufacturing excellence, while the upcoming Q2FY27 earnings call on Oct 27 will be the next key catalyst. No material headwinds or bullish triggers have emerged in the latest cycle. Investors should watch the Q2 results for clarity on revenue momentum and margin trajectory.

Neutral 2
  • New Global CTO appointed Nov 4

    Cipla appointed Vikram Janakiraman as Global Chief Technical Operating Officer effective December 7, 2026. He brings 30 years of pharma operations experience, previously leading global manufacturing at Glenmark.

  • Q2FY27 earnings call scheduled Oct 13

    Cipla will release Q2FY27 unaudited financial results on October 27, 2026, with an earnings conference call at 4:00 pm IST.

Quarterly Results

₹ Cr
CIPLA quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
6,329
6,678
6,604
6,163
6,694
7,051
7,073
6,730
6,957
7,589
7,074
6,541
7,119
7,404
Expenses
4,835
4,944
4,856
4,847
4,978
5,165
5,084
5,192
5,179
5,695
5,819
5,586
5,927
6,016
Operating Profit
1,494
1,734
1,748
1,316
1,716
1,886
1,989
1,538
1,778
1,895
1,255
955
1,192
—
OPM %
24%
26%
26%
21%
26%
27%
28%
23%
26%
25%
18%
15%
17%
—
Other Income
136
176
−10
249
160
191
222
289
259
269
−70
148
211
—
Interest
16
26
30
18
18
15
15
14
14
13
14
13
17
17
Depreciation
239
290
233
288
247
272
280
309
253
297
278
383
304
345
PBT
1,375
1,594
1,474
1,259
1,611
1,789
1,916
1,504
1,770
1,854
893
707
1,082
1,172
Tax %
28%
28%
28%
26%
27%
27%
17%
19%
27%
27%
24%
22%
27%
27%
Net Profit
998
1,155
1,068
932
1,175
1,305
1,575
1,214
1,292
1,353
674
543
786
852
EPS (₹)
12.33
14.01
13.08
11.63
14.58
16.13
19.45
15.13
16.06
16.73
8.37
6.87
9.77
—

Sep 2026: from the results filed on 27 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
CIPLA profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
11,345
13,790
14,394
15,156
16,362
17,132
19,160
21,763
22,753
25,774
27,548
28,163
28,324
Expenses
9,183
11,310
11,898
12,329
13,265
13,926
14,907
17,211
17,726
19,483
20,420
22,280
23,027
Operating Profit
2,163
2,480
2,496
2,826
3,097
3,206
4,252
4,553
5,027
6,291
7,128
5,883
5,297
OPM %
19%
18%
17%
19%
19%
19%
22%
21%
22%
24%
26%
21%
19%
Other Income
164
208
208
280
477
344
266
99
293
552
862
606
558
Interest
168
207
159
114
168
197
161
106
110
90
62
54
57
Depreciation
505
754
1,323
1,323
1,326
1,175
1,068
1,052
1,172
1,051
1,107
1,211
1,262
PBT
1,654
1,727
1,222
1,669
2,079
2,178
3,290
3,493
4,038
5,702
6,821
5,224
4,536
Tax %
24%
19%
15%
15%
27%
29%
27%
27%
30%
27%
22%
26%
—
Net Profit
1,229
1,383
1,035
1,417
1,492
1,500
2,389
2,547
2,833
4,154
5,269
3,862
3,356
EPS (₹)
14.71
16.93
12.51
17.52
18.96
19.18
29.82
31.19
34.71
51.05
65.28
48.02
41.74
Div. Payout %
14%
12%
16%
17%
16%
21%
17%
16%
24%
25%
25%
27%
—

Balance Sheet

₹ Cr
CIPLA balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
161
161
161
161
161
161
161
161
161
161
162
162
Reserves
10,641
11,356
12,383
14,068
14,851
15,602
18,165
20,680
23,246
26,545
31,032
34,270
Borrowings
1,703
5,202
4,113
4,098
4,316
2,816
2,014
1,056
803
559
438
614
Other Liabilities
3,166
4,331
4,213
4,346
4,433
4,843
4,514
4,960
5,089
5,267
5,702
7,297
Total Liabilities
15,670
21,049
20,869
22,673
23,762
23,423
24,855
26,857
29,300
32,533
37,334
42,343
Fixed Assets
6,830
9,368
9,492
9,950
9,608
9,683
9,516
9,683
9,160
9,607
10,006
12,434
CWIP
581
2,061
1,683
981
676
825
969
766
1,093
1,153
1,566
2,042
Investments
640
759
973
1,259
2,554
1,471
2,710
2,551
3,662
5,449
7,933
8,223
Other Assets
7,620
8,862
8,721
10,483
10,923
11,444
11,661
13,857
15,384
16,323
17,828
19,643
Total Assets
15,670
21,049
20,869
22,673
23,762
23,423
24,855
26,857
29,300
32,533
37,334
42,343

Cash Flow

₹ Cr
CIPLA cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1,173
1,741
2,382
1,463
1,691
3,068
3,755
3,326
3,238
4,134
5,005
3,940
Investing
−950
−4,533
−1,304
−834
−1,688
114
−2,374
−1,858
−2,376
−2,982
−3,682
−2,234
Financing
165
3,104
−1,326
−385
−349
−2,949
−1,240
−1,600
−958
−1,200
−1,293
−1,234
Net Cash Flow
388
312
−248
243
−345
234
141
−132
−97
−49
30
473
Free Cash Flow
548
688
1,284
723
1,187
2,083
2,964
2,645
2,102
2,819
3,490
928
CFO/EBITDA
72
91
113
77
74
122
113
98
90
91
94
94

Ratios

CIPLA financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
64
62
65
75
93
83
66
57
65
68
73
73
Inventory Days
329
273
239
271
250
267
232
230
228
217
231
252
Days Payable
126
106
108
142
123
139
103
108
112
102
116
123
Cash Conversion Cycle
267
230
196
204
220
211
195
180
181
182
188
202
Working Capital Days
89
−10
99
118
132
113
94
95
113
120
128
106
ROCE %
15%
13%
7%
9%
11%
12%
17%
17%
18%
23%
23%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Cipla insights

73 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • DIIs 34.94%
  • Promoters 29.21%
  • FIIs 20.25%
  • Public 13.41%
  • Others 2.19%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Cipla

What does Cipla Ltd do?
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs
Where is Cipla Ltd (CIPLA) listed?
Cipla Ltd trades as CIPLA on the NSE and under code 500087 on the BSE.
Which sector does Cipla Ltd belong to?
Cipla Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Cipla Ltd?
Cipla Ltd trades at a PE ratio of 33.59 as of 4 Nov 2026, on earnings per share of ₹41.74, against a book value of ₹438.13 per share.
What is the 52-week high and low of Cipla Ltd?
Over the last 52 weeks Cipla Ltd has traded between ₹1,165.7 and ₹1,539.7 as of 4 Nov 2026.
Does Cipla Ltd pay dividends?
Cipla Ltd has a dividend yield of 0.93%.
What is the Return on Equity (ROE) of Cipla Ltd?
Cipla Ltd reported a return on equity of 11.60%. Its debt-to-equity ratio is 0.02.

Company Information

Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs

Website cipla.com
CEO Mr. Umang Vohra B.E., M.B.A.
Employees 30,313
Listed 8 Feb 1995
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CIPLA.md for Cipla Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month